Nils Spidsøe

Sintef TTO AS is a venture capital firm located in Trondheim, Norway. Sintef TTO is a wholly-owned subsidiary of SINTEF, established in 1950, one of the largest independent research organizations in the Nordic region. Their areas of research encompass information and communications technology, technology management, marine activities, materials science and applied chemistry, health, petroleum, energy, and construction. Sintef TTO, as the group's development firm, is responsible for their innovation activities. They are also the owner and manager of SINTEF's Intellectual Property Rights (IPR). They are the investment manager of several funds, namely SINTEF Venture III AS, Sinvent Venture, and SpinOutVenture II AS.

MarBiLeads AS engages in the development of drug candidates for infections and cancer based on marine microorganisms. The company was founded on December 22, 2010 and is headquartered in Trondheim, Norway.

Funzionano AS produces and sells functional nanotechnology-based hybrid polymers. It is a generic technology platform that has been developed at SINTEF materials and chemistry. The company is headquartered in Trondheim, Norway.

Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.